Nivolumab companion diagnostic - BiodesixAlternative Names: BDX 008
Latest Information Update: 13 Nov 2015
At a glance
- Originator Biodesix
- Class Diagnostic agents; Protein diagnostics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Malignant melanoma